• 去甲氧柔红霉素与柔红霉素在初治急性髓系白血病诱导治疗中的疗效与安全性分析
  • Efficacy and safety of the treatment of Methoxy-DNR and DNR in the induction of primary acute myeloid leukemia
  • 李亮.去甲氧柔红霉素与柔红霉素在初治急性髓系白血病诱导治疗中的疗效与安全性分析[J].内科急危重症杂志,2017,23(5):
    扫码阅读全文 本文二维码信息
    DOI:
    中文关键词:  去甲氧柔红霉素,柔红霉素,急性髓系白血病
    英文关键词:Neomycin daunorubicin, daunorubicin, acute myeloid leukemia
    基金项目:
    作者单位E-mail
    李亮 蚌埠医学院第二附属医院血液内科 ar18131@163.com 
    摘要点击次数: 2342
    全文下载次数: 3380
    中文摘要:
          目的:比较分析去甲氧柔红霉素联合阿糖胞苷(IA)方案与柔红霉素联合阿糖胞苷(DA)方案在初治成人急性髓系白血病(AML)(非M3)诱导治疗中的疗效及安全性。 方法:选取我科2011年1月至2016年12月收治的30例AML患者,随机将患者分为IA(研究)组14例,DA(对照)组16例。通过诱导化疗后,观察两组患者的完全缓解率,总有效率以及不良反应率。结果:IA组的完全缓解率为71.43%,总有效率为92.88%;DA组的完全缓解率为43.75%,总有效率为68.75%;两组有效率之间比较差异有统计学意义(P<0.05),而两组之间不良反应率比较差异无统计学意义(P>0.05)。结论:IA方案在初治成人AML(非M3)诱导化疗中比DA方案疗效更好,且不良反应率无明显差异。
    英文摘要:
          Objective: To compare the efficacy of daunorubicin combined with cytarabine (Ara) and daunorubicin combined with cytosine arabinoside (DA) in the treatment of adult acute myeloid leukemia (AML) M3) in the induction of treatment efficacy and safety. METHODS: Thirty patients with AML who were admitted to our hospital from January 2011 to December 2016 were randomly divided into IA group (n = 14) and DA (n = 16). After induction of chemotherapy, the complete remission rate, total effective rate and adverse reaction rate were observed. Results: Complete remission rate was 71.43% and total effective rate was 92.88% in group IA, 43.75% and 68.75% respectively. The difference between the two groups was significant (P <0.05). There was no significant difference between the two groups in the adverse reaction rate (P> 0.05). Conclusion: IA regimen is better than DA regimen in the treatment of AML (non - M3) induction chemotherapy, and the adverse reaction rate is not significantly different.